KRAS and cancer: We tested three cancer cell lines with active KRAS mutations (MDA-MB-231, HCT116, and A549), three cancer cell lines with WT KRAS (MCF7, HT-29, and NCI-H520), and a normal cell line (HME1) (Fig. 5B).